We are live on ! Find out more
ADPT icon

Adaptive Biotechnologies

133 hedge funds and large institutions have $2.58B invested in Adaptive Biotechnologies in 2019 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 44 increasing their positions, 29 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 22

52% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 29

25% more funds holding in top 10

Funds holding in top 10: 45 (+1)

14% more funds holding

Funds holding: 117133 (+16)

4.13% more ownership

Funds ownership: 65.29%69.42% (+4.1%)

3% more capital invested

Capital invested by funds: $2.5B → $2.58B (+$87.1M)

68% less call options, than puts

Call options by funds: $1.61M | Put options by funds: $4.99M

Holders
133
Holders Change
+16
Holders Change %
+13.68%
% of All Funds
2.62%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.1%
New
43
Increased
44
Reduced
29
Closed
22
Calls
$1.61M
Puts
$4.99M
Net Calls
-$3.38M
Net Calls Change
-$5.14M
Name Holding Trade Value Shares
Change
Change in
Stake
Victory Capital Management
51
Victory Capital Management
Texas
$2.29M -$333K -11,604 -13%
Principal Financial Group
52
Principal Financial Group
Iowa
$2.21M +$107K +3,743 +5%
Susquehanna International Group
53
Susquehanna International Group
Pennsylvania
$1.86M +$598K +20,821 +50%
RCM
54
Ratan Capital Management
Florida
$1.84M +$579K +20,178 +49%
CI Investments Inc
55
CI Investments Inc
Ontario, Canada
$1.79M
Citadel Advisors
56
Citadel Advisors
Florida
$1.73M -$1.73M -60,279 -51%
HighTower Advisors
57
HighTower Advisors
Illinois
$1.72M +$1.65M +57,375 New
SEI Investments
58
SEI Investments
Pennsylvania
$1.68M +$794K +27,647 +97%
N
59
Nuveen
North Carolina
$1.63M -$44.1K -1,534 -3%
PVI
60
Pura Vida Investments
New York
$1.62M +$1.55M +54,010 New
UBS AM
61
UBS AM
Illinois
$1.53M -$8.04K -280 -0.5%
Federated Hermes
62
Federated Hermes
Pennsylvania
$1.41M +$150K +5,235 +12%
TCM
63
Tuttle Capital Management
Connecticut
$1.27M +$1.22M +42,558 New
Bank of New York Mellon
64
Bank of New York Mellon
New York
$1.27M +$333K +11,606 +38%
CGL
65
Clarius Group LLC
Washington
$1.17M +$1.14M +39,596 New
MA
66
MYDA Advisors
New York
$1.17M +$144K +5,000 +15%
PPA
67
Parametric Portfolio Associates
Washington
$1.15M +$411K +14,300 +59%
ZP
68
Zimmer Partners
New York
$1.09M
Allianz Asset Management
69
Allianz Asset Management
Germany
$1.03M -$809K -28,174 -45%
Macquarie Group
70
Macquarie Group
Australia
$914K +$877K +30,553 New
New York State Common Retirement Fund
71
New York State Common Retirement Fund
New York
$893K +$462K +16,100 +117%
California Public Employees Retirement System
72
California Public Employees Retirement System
California
$862K +$827K +28,800 New
FAM
73
Fred Alger Management
New York
$843K -$30.7M -1,068,498 -97%
Wellington Management Group
74
Wellington Management Group
Massachusetts
$842K -$3.21M -111,843 -80%
California State Teachers Retirement System (CalSTRS)
75
California State Teachers Retirement System (CalSTRS)
California
$825K +$6.81K +237 +0.9%

ADPT Hedge Fund Activity: Q4 2019 in Review

133 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q4 2019, worth a combined $2.58B — up 3.5% from $2.5B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new ADPT positions and 22 closed out — a net gain of 21 holders — while 44 added to existing stakes and 29 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $42.9M. The largest seller was Fred Alger Management, cutting an estimated $30.7M.

  • 133 institutional investors held Adaptive Biotechnologies (ADPT) as of Q4 2019, up from 117 in Q3 2019.
  • Funds reported $2.58B of Adaptive Biotechnologies stock for Q4 2019, up 3.5% quarter-over-quarter.
  • 43 funds opened new Adaptive Biotechnologies positions in Q4 2019 and 22 closed out, a net change of +21 holders.
  • The largest Adaptive Biotechnologies buyer in Q4 2019 was T. Rowe Price Associates, an estimated $42.9M added.
  • The largest Adaptive Biotechnologies seller in Q4 2019 was Fred Alger Management, an estimated $30.7M sold.

Based on aggregated 13F filings for Q4 2019.